Promethazine is a first generation antihistamine sold under names like Phenergan and used for allergy symptoms, nausea, motion sickness, and sedation before certain procedures. It is not one of the substances a standard workplace or clinical drug test panel is designed to detect. But the question gets more complicated fast, because promethazine is also compounded with codeine in a prescription cough syrup, and codeine is a federally controlled opioid that will show up on an opiate screen. Understanding the difference between the two products, and between a presumptive screening result and a confirmed laboratory result, is the whole answer.
Promethazine by itself is not a targeted analyte
Standard urine, oral fluid, and dip card panels are built around specific drug classes: amphetamines, opiates, cocaine metabolite, THC, PCP, and similar groups. Promethazine is a phenothiazine antihistamine, not a controlled substance, and the FDA prescribing information for promethazine hydrochloride lists it for allergy relief, sedation, nausea, and motion sickness, with no scheduling under the Controlled Substances Act. No panel is manufactured to flag promethazine on its own, and a person taking only promethazine should not expect it to appear as a targeted result.
The catch: cross reactivity on amphetamine immunoassays
Immunoassay screening tests work by looking for a chemical shape, not a specific molecule, which is why they are called presumptive tests. A compound that is structurally similar enough to the target drug class can sometimes trigger a nonnegative screening result even though it is not the drug the panel is looking for. This has been documented for promethazine on amphetamine class immunoassays. A peer-reviewed review of urine drug screening pitfalls published through the National Institutes of Health found that patients taking promethazine produced nonnegative amphetamine immunoassay results in a meaningful share of tested cases, and the same review noted that an earlier published study tied the effect to promethazine doses of 50 milligrams or more. A separate NIH-indexed review of toxicology testing pitfalls also lists promethazine among the medications reported to interfere with certain screening immunoassays and produce results that do not reflect actual drug class use.
This is exactly what confirmation testing exists to resolve. A nonnegative screen is not a finding of drug use. It is a signal that a laboratory needs to run a definitive method, typically gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry, on the same specimen. Confirmation testing identifies the exact molecule present rather than a chemical family, so it distinguishes actual amphetamine or methamphetamine from a promethazine related cross reaction. If promethazine caused the nonnegative screen, confirmation will not find amphetamine or methamphetamine at the confirmation cutoff, and the result should come back negative once reviewed.
Promethazine with codeine syrup is a different product entirely
Promethazine is also formulated with codeine as an oral solution, prescribed for cough suppression. This combination contains an actual opioid, and it behaves nothing like promethazine alone on a drug test. Codeine is metabolized in the body partly into morphine, so an opiate immunoassay can flag a specimen after someone takes promethazine with codeine syrup, and confirmation testing will identify codeine, and often its morphine metabolite, at quantifiable levels. The FDA label for promethazine and codeine phosphate oral solution confirms the product contains codeine phosphate as an active ingredient and carries standard opioid warnings about sedation, respiratory depression, and abuse potential.
Because it contains a limited quantity of a narcotic combined with a non-narcotic active ingredient, promethazine with codeine falls under Schedule V of the Controlled Substances Act. Federal regulations at 21 CFR 1308.15 place preparations containing not more than 200 milligrams of codeine per 100 milliliters, combined with one or more non-narcotic active medicinal ingredients, in Schedule V, which is the least restrictive controlled substance schedule but still requires a valid prescription to dispense in most states. A positive opiate result tied to this product is a real, expected pharmacological finding, not a testing error.
Promethazine alone vs promethazine with codeine on a drug test panel
| Product | Active ingredients | Controlled substance status | Typical screening result | What confirmation shows |
|---|---|---|---|---|
| Promethazine alone (Phenergan and generics) | Promethazine hydrochloride | Not scheduled under the Controlled Substances Act | Usually negative; occasional nonnegative on amphetamine class immunoassays | No amphetamine or methamphetamine identified if the nonnegative screen was a cross reaction |
| Promethazine with codeine oral solution | Promethazine hydrochloride and codeine phosphate | Schedule V controlled substance | Nonnegative on an opiate immunoassay | Codeine identified, often with a morphine metabolite, at quantifiable levels |
| Promethazine, phenylephrine, and codeine syrup | Promethazine hydrochloride, phenylephrine, and codeine phosphate | Schedule V controlled substance | Nonnegative on an opiate immunoassay | Codeine identified, often with a morphine metabolite, at quantifiable levels |
How the medical review officer handles either scenario
A screening result is never the final word in a properly run program. Any nonnegative screen goes to laboratory confirmation, and any confirmed nonnegative result on a regulated or employer program is reviewed by a medical review officer, a licensed physician trained to interpret drug test results in a clinical and legal context. The MRO process gives the employee or candidate a confidential opportunity to explain a confirmed result, and a valid, current prescription for promethazine with codeine, verified with the prescribing practitioner or pharmacy, is a legitimate medical explanation. If the codeine finding matches a verified prescription taken as directed, the MRO generally reports the result to the employer as negative for testing purposes, while still documenting the medical review. Keeping a copy of the prescription label or pharmacy printout on hand speeds this step considerably.
Because codeine converts to morphine in the body, a confirmed positive that traces back to promethazine with codeine can look similar on paper to a positive tied to a morphine or heroin related product. This is exactly why the confirmation and MRO steps matter for opiate results generally, not just for codeine syrup. Readers comparing opiate detection more broadly may find it useful to see how a related opioid is handled in our guide to morphine and the opiate panel, which covers cutoffs and confirmation in more depth.
What this means for testing programs and employers
Employers should never treat a nonnegative immunoassay screen as a final adverse finding, and should never ask an employee or applicant to disclose their full medication list before a screen is even run. The correct sequence is screen, confirm any nonnegative result in a certified laboratory, and route confirmed nonnegative results through a medical review officer who can request documentation privately. This protects both the integrity of the testing program and the privacy of employees who take legitimate prescription medications. A program built around quality immunoassay screening devices paired with laboratory confirmation, such as the drug test cups used across many workplace programs, is designed with this two step process in mind rather than treating a screen alone as a verdict.
Employers and testing administrators should also remember that state laws on prescription privacy, disability accommodation, and adverse action procedures vary, and a confirmed positive tied to a documented prescription should generally not be treated the same as an undocumented illicit drug finding. Because these rules differ by state and by industry, employers should consult their own legal counsel and their MRO's written protocol rather than relying on a generalized rule for every situation.
Frequently asked questions
Does promethazine alone show up on a standard drug test?
Not as a targeted result. Promethazine is not one of the drug classes a standard panel screens for, though it has been documented as an occasional cause of a nonnegative result on amphetamine class immunoassays, which confirmation testing resolves.
Will promethazine with codeine syrup test positive for opiates?
Yes. Promethazine with codeine oral solution contains codeine, an opioid, and an opiate immunoassay can return a nonnegative result after use, with confirmation testing identifying codeine and often its morphine metabolite.
Can promethazine cause a false positive for amphetamines?
Documented cases exist where promethazine produced a nonnegative result on an amphetamine class immunoassay screen. This is a screening level cross reaction. Confirmation testing with gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry identifies the actual substance present and resolves the question.
What happens if I test positive because of a promethazine and codeine prescription?
A confirmed nonnegative result is reviewed by a medical review officer, who contacts the individual confidentially to ask about current medications. A valid, verifiable prescription taken as directed is a legitimate medical explanation that the MRO documents as part of the review.
Is promethazine with codeine a controlled substance?
Yes. Combination products containing limited amounts of codeine with a non-narcotic active ingredient, including promethazine with codeine, are placed in Schedule V of the Controlled Substances Act and require a valid prescription to dispense in most states.
Does confirmation testing tell the difference between codeine and other opioids?
Yes. Confirmation methods identify the specific molecule present rather than a broad drug class, which is how a laboratory and an MRO can distinguish a codeine and morphine metabolite pattern consistent with promethazine and codeine syrup from other opioid sources.
This article is general information about drug testing science and process, not legal or medical advice. Employers should consult qualified legal counsel and their medical review officer for guidance specific to their program, and individuals with questions about a specific medication or test result should speak with a licensed medical provider.